Another preventive measure is monoclonal antibodies — artificially created proteins that can be given to infants to assist ...

It is a mistake to claim that there is not widespread research into the effectiveness of vaccines, especially those given to ...

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

A medical panel appointed by Health Secretary Robert F. Kennedy Jr. voted Thursday to recommend a new monoclonal antibody ...

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent ...

A new national guideline provides evidence-based recommendations for diagnosing, treating, and preventing pediatric respiratory syncytial virus (RSV) infections in China. Addressing 12 clinical ...

Frailty strongly predicts worse RSV outcomes in older adults, highlighting the need for targeted care as aging populations face rising infection risks.

This report describes three cases of clade Ib MPXV infection in pregnant women (one in each trimester of gestation) with molecular and histopathological evidence of transplacental transmission.

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young children, placing a significant burden on families, hospitals, and the healthcare system. Recent ...

References: Moderna receives US FDA approval for RSV vaccine, mResvia, in adults aged 18-59 at increased risk for RSV disease. News release. Moderna.